Autopsy report · NCT03756922

A DDI Study of FDL169 and FDL176 in Healthy Subjects

“Business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 78 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1, Phase 2

Sponsor

Flatley Discovery Lab LLC

Sponsor type

University, hospital or other

Conditions

Cystic Fibrosis

Interventions

FDL169; FDL176

Participants

78 (planned, not actual)

Sites

1

Countries

United Kingdom

Trials that died the same way

• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
  “Business Reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.